Gilead's 4-drug combo shows early promise against hepatitis C

03/8/2011 | Bloomberg

A four-drug combination from Gilead Sciences showed promise during an early-stage trial in eliminating hepatitis C virus, RBC Capital Markets analysts said. The result supports an ongoing Phase II trial of the drug, which consists of Gilead's compounds GS-9256 and GS-9190 plus standard treatments ribavirin and pegylated interferon.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care